{
    "hands_on_practices": [
        {
            "introduction": "This first exercise establishes the foundational principle of intention-to-treat (ITT) analysis. You will directly compare an ITT estimate with an \"as-treated\" estimate to see how breaking randomization in the analysis can lead to different conclusions. This practice highlights why ITT is crucial for obtaining an unbiased estimate of the effect of *assigning* an intervention. ",
            "id": "4603081",
            "problem": "A randomized controlled trial (RCT) assigns $n=1000$ participants in a $1:1$ ratio to a treatment arm and a control arm at baseline. By design, $10\\%$ of those randomized to treatment discontinue and receive control, and $20\\%$ of those randomized to control cross over and receive treatment. Investigators collect binary outcomes (event versus no event) for all participants and produce the following observed $2\\times 2$ outcome counts by randomized group (for an intention-to-treat classification) and by actual treatment received (for an as-treated classification).\n\nBy randomized group (intention-to-treat classification):\n- Randomized to treatment: $64$ events, $436$ non-events (total $500$).\n- Randomized to control: $85$ events, $415$ non-events (total $500$).\n\nBy actual treatment received (as-treated classification):\n- Actually received treatment: $67$ events, $483$ non-events (total $550$).\n- Actually received control: $82$ events, $368$ non-events (total $450$).\n\nAssume that all participants are followed completely and that outcome ascertainment is unbiased. Using the foundational definitions that randomization aims to balance both measured and unmeasured confounders across arms at baseline, that intention-to-treat analysis classifies participants by randomized assignment regardless of adherence, and that the risk (cumulative incidence) in a group is the proportion of participants with events, compute the following:\n\n1. The intention-to-treat risk difference, defined as $RD_{\\text{ITT}} = \\text{risk}_{\\text{randomized to treatment}} - \\text{risk}_{\\text{randomized to control}}$, using the provided $2\\times 2$ counts by randomized group.\n\n2. The as-treated risk difference, defined as $RD_{\\text{AT}} = \\text{risk}_{\\text{actually treated}} - \\text{risk}_{\\text{actually control}}$, using the provided $2\\times 2$ counts by actual treatment received.\n\nExpress both risk differences as decimals and round your answers to four significant figures. Report your final answers in the order $\\left(RD_{\\text{ITT}}, RD_{\\text{AT}}\\right)$.",
            "solution": "The problem requires the computation of two distinct measures of treatment effect, the intention-to-treat risk difference ($RD_{\\text{ITT}}$) and the as-treated risk difference ($RD_{\\text{AT}}$), from data provided for a randomized controlled trial (RCT).\n\n### Step 1: Problem Validation\n\nFirst, we must validate the problem statement.\n\n**1.1. Extracted Givens:**\n- Total participants, $n = 1000$.\n- Randomization: $1:1$ ratio to a treatment arm and a control arm.\n- Non-adherence: $10\\%$ of those randomized to treatment discontinue and receive control; $20\\%$ of those randomized to control cross over and receive treatment.\n- Intention-to-treat (ITT) data (by randomized group):\n    - Randomized to treatment: $64$ events, $436$ non-events, total $500$.\n    - Randomized to control: $85$ events, $415$ non-events, total $500$.\n- As-treated (AT) data (by actual treatment received):\n    - Actually received treatment: $67$ events, $483$ non-events, total $550$.\n    - Actually received control: $82$ events, $368$ non-events, total $450$.\n- Assumption: Complete follow-up and unbiased outcome ascertainment.\n- Definition of risk: Proportion of participants with events in a group.\n- Definition of $RD_{\\text{ITT}}$: $\\text{risk}_{\\text{randomized to treatment}} - \\text{risk}_{\\text{randomized to control}}$.\n- Definition of $RD_{\\text{AT}}$: $\\text{risk}_{\\text{actually treated}} - \\text{risk}_{\\text{actually control}}$.\n\n**1.2. Validation using Extracted Givens:**\nThe problem is scientifically grounded, employing standard concepts and terminology from epidemiology and clinical trials (RCT, intention-to-treat, as-treated, risk, risk difference). The given data are internally consistent. Let's verify the consistency of the group sizes based on the stated non-adherence rates.\n- Participants randomized to the treatment arm: $N_{\\text{rand_tx}} = 1000 \\times \\frac{1}{2} = 500$.\n- Participants randomized to the control arm: $N_{\\text{rand_ctl}} = 1000 \\times \\frac{1}{2} = 500$. These match the ITT table.\n- Participants randomized to treatment who adhered: $500 \\times (1 - 0.10) = 500 \\times 0.90 = 450$.\n- Participants randomized to treatment who discontinued (and received control): $500 \\times 0.10 = 50$.\n- Participants randomized to control who adhered: $500 \\times (1 - 0.20) = 500 \\times 0.80 = 400$.\n- Participants randomized to control who crossed over (and received treatment): $500 \\times 0.20 = 100$.\n- Total who actually received treatment: (Adherers from treatment arm) + (Crossovers from control arm) = $450 + 100 = 550$. This matches the AT table.\n- Total who actually received control: (Discontinuers from treatment arm) + (Adherers from control arm) = $50 + 400 = 450$. This also matches the AT table.\n\nThe problem is well-posed, as all necessary data and definitions are provided for the required calculations. The language is objective and precise. The scenario is realistic. No flaws are identified.\n\n**1.3. Verdict:**\nThe problem is valid. We may proceed with the solution.\n\n### Step 2: Solution Derivation\n\nThe problem requires the calculation of two risk differences based on two different classifications of the study population.\n\n**2.1. Calculation of the Intention-to-Treat Risk Difference ($RD_{\\text{ITT}}$)**\n\nThe intention-to-treat analysis compares outcomes based on the initial random assignment, regardless of the treatment actually received. This approach preserves the prognostic balance between the groups created by randomization and provides an unbiased estimate of the effect of *assigning* a treatment in a population with expected levels of non-adherence.\n\nLet $R_{\\text{rand_tx}}$ be the risk in the group randomized to treatment and $R_{\\text{rand_ctl}}$ be the risk in the group randomized to control.\nThe number of participants randomized to treatment is $N_{\\text{rand_tx}} = 64 + 436 = 500$.\nThe number of events in this group is $E_{\\text{rand_tx}} = 64$.\nThe risk is:\n$$R_{\\text{rand_tx}} = \\frac{E_{\\text{rand_tx}}}{N_{\\text{rand_tx}}} = \\frac{64}{500} = 0.128$$\n\nThe number of participants randomized to control is $N_{\\text{rand_ctl}} = 85 + 415 = 500$.\nThe number of events in this group is $E_{\\text{rand_ctl}} = 85$.\nThe risk is:\n$$R_{\\text{rand_ctl}} = \\frac{E_{\\text{rand_ctl}}}{N_{\\text{rand_ctl}}} = \\frac{85}{500} = 0.170$$\n\nThe intention-to-treat risk difference is defined as:\n$$RD_{\\text{ITT}} = R_{\\text{rand_tx}} - R_{\\text{rand_ctl}}$$\n$$RD_{\\text{ITT}} = 0.128 - 0.170 = -0.042$$\nRounding to four significant figures, we get $RD_{\\text{ITT}} = -0.04200$.\n\n**2.2. Calculation of the As-Treated Risk Difference ($RD_{\\text{AT}}$)**\n\nThe as-treated analysis compares outcomes based on the treatment that participants actually received. This analysis is observational in nature and does not preserve the benefits of randomization. It is susceptible to confounding by indication, as the factors that lead a participant to switch or discontinue treatment may also be related to their risk of the outcome.\n\nLet $R_{\\text{actual_tx}}$ be the risk in the group that actually received treatment and $R_{\\text{actual_ctl}}$ be the risk in the group that actually received control.\nFrom the provided table, the number of participants who actually received treatment is $N_{\\text{actual_tx}} = 67 + 483 = 550$.\nThe number of events in this group is $E_{\\text{actual_tx}} = 67$.\nThe risk is:\n$$R_{\\text{actual_tx}} = \\frac{E_{\\text{actual_tx}}}{N_{\\text{actual_tx}}} = \\frac{67}{550} \\approx 0.12181818...$$\n\nThe number of participants who actually received control is $N_{\\text{actual_ctl}} = 82 + 368 = 450$.\nThe number of events in this group is $E_{\\text{actual_ctl}} = 82$.\nThe risk is:\n$$R_{\\text{actual_ctl}} = \\frac{E_{\\text{actual_ctl}}}{N_{\\text{actual_ctl}}} = \\frac{82}{450} \\approx 0.18222222...$$\n\nThe as-treated risk difference is defined as:\n$$RD_{\\text{AT}} = R_{\\text{actual_tx}} - R_{\\text{actual_ctl}}$$\n$$RD_{\\text{AT}} = \\frac{67}{550} - \\frac{82}{450} \\approx 0.12181818... - 0.18222222... = -0.06040404...$$\nRounding to four significant figures, we get $RD_{\\text{AT}} = -0.06040$.\n\nThe problem asks for both results reported in the order $(RD_{\\text{ITT}}, RD_{\\text{AT}})$.",
            "answer": "$$\\boxed{\\begin{pmatrix} -0.04200 & -0.06040 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Building on the core definition of ITT, this practice explores a common real-world consequence: the attenuation of the treatment effect. By working through a hypothetical scenario with non-adherence, you will calculate how discontinuation and crossover \"dilute\" the observed effect in an ITT analysis compared to an idealized per-protocol analysis. This exercise demonstrates why the ITT effect is often considered a measure of \"effectiveness\" in a real-world setting rather than pure \"efficacy.\" ",
            "id": "4603144",
            "problem": "A randomized, two-arm clinical trial evaluates a preventive intervention over one year. Participants are randomly assigned at baseline to either the intervention arm or the control arm. Let the cumulative risk of the outcome over one year for an individual who receives the intervention continuously be denoted by $R_T$, and for an individual who receives the control continuously be denoted by $R_C$. Suppose $R_T = 0.10$ and $R_C = 0.20$. Randomization ensures exchangeability at baseline, there is no loss to follow-up, and there is no unmeasured confounding affecting deviations from the assigned protocol.\n\nHowever, mid-year deviations occur:\n- In the intervention arm, a proportion $0.60$ adhere to the protocol (receive intervention continuously; risk $0.10$), while a proportion $0.40$ discontinue and receive control for the remainder of follow-up. For these discontinuers, the one-year risk is $0.16$.\n- In the control arm, a proportion $0.65$ adhere to the protocol (receive control continuously; risk $0.20$), while a proportion $0.35$ switch mid-year to the intervention. For these switchers, the one-year risk is $0.14$.\n\nDefinitions:\n- The intention-to-treat (ITT) effect compares risks by randomized assignment, using all participants as assigned regardless of deviations. The ITT risk in the intervention arm is the average risk across adherers and discontinuers weighted by their observed proportions, and analogously for the control arm.\n- The per-protocol (PP) effect compares risks under full adherence to the assigned protocol, contrasting those who remained on intervention continuously with those who remained on control continuously.\n\nUsing the foundational definitions of risk $R$ (probability of the outcome over one year) and risk ratio $\\mathrm{RR} = R_1/R_0$ (where $R_1$ is the risk in the exposed/intervention group and $R_0$ is the risk in the unexposed/control group), reason from these data about the direction and magnitude of attenuation of the ITT risk ratio compared to the per-protocol risk ratio, without assuming any unmeasured confounding. Which statement best captures this relationship?\n\nA. The intention-to-treat risk ratio equals the per-protocol risk ratio at $0.50$ because randomization balances nonadherence, so deviations do not affect the contrast.\n\nB. The intention-to-treat risk ratio is attenuated toward the null relative to the per-protocol risk ratio, approximately $0.69$ versus $0.50$, due to discontinuation in the intervention arm increasing its average risk and switching in the control arm decreasing its average risk.\n\nC. The intention-to-treat risk ratio is stronger (farther from $1$) than the per-protocol risk ratio, approximately $0.40$, because excluding nonadherers reduces bias and increases the contrast.\n\nD. The intention-to-treat risk ratio reverses direction (greater than $1$), approximately $1.10$, due to differential nonadherence overwhelming randomization.",
            "solution": "The problem statement is subjected to validation before proceeding with a solution.\n\n### Step 1: Extract Givens\n- A randomized, two-arm (intervention, control) clinical trial with a one-year follow-up.\n- $R_T$: Cumulative risk over one year for an individual receiving the intervention continuously. $R_T = 0.10$.\n- $R_C$: Cumulative risk over one year for an individual receiving the control continuously. $R_C = 0.20$.\n- At baseline, randomization ensures exchangeability.\n- There is no loss to follow-up.\n- There is no unmeasured confounding affecting deviations from the assigned protocol.\n- **Intervention Arm Deviations:**\n  - Proportion of adherers: $0.60$. Their risk is $0.10$.\n  - Proportion of discontinuers (switch to control): $0.40$. Their one-year risk is $0.16$.\n- **Control Arm Deviations:**\n  - Proportion of adherers: $0.65$. Their risk is $0.20$.\n  - Proportion of switchers (switch to intervention): $0.35$. Their one-year risk is $0.14$.\n- **Definition of Intention-to-Treat (ITT) effect:** Compares risks by randomized assignment. The risk in each arm is the average risk of all participants as assigned, weighted by the proportions of adherers and non-adherers.\n- **Definition of Per-Protocol (PP) effect:** Compares risks under full adherence, contrasting those on continuous intervention ($R_T$) with those on continuous control ($R_C$).\n- **Effect measure:** Risk Ratio, $\\mathrm{RR} = R_1/R_0$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n1.  **Scientific Soundness:** The scenario is a standard and realistic representation of a clinical trial with protocol deviations. The concepts of ITT analysis, PP analysis, risk, risk ratio, adherence, and non-adherence (crossover/discontinuation) are fundamental principles in epidemiology and biostatistics. All provided risk values are valid probabilities between $0$ and $1$. The risk for participants who deviate ($0.16$ and $0.14$) lies between the risks for continuous intervention ($0.10$) and continuous control ($0.20$), which is logical for individuals who experience a mix of exposures.\n2.  **Well-Posedness:** The problem is fully specified. It provides all necessary numerical data and clear definitions to calculate both the ITT and PP risk ratios. The question is unambiguous and asks for a specific comparison.\n3.  **Objectivity:** The problem is stated in precise, quantitative terms, free from subjective or biased language.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be derived.\n\n### Derivation of the Solution\n\nThe task is to compute the per-protocol risk ratio ($\\mathrm{RR}_{\\mathrm{PP}}$) and the intention-to-treat risk ratio ($\\mathrm{RR}_{\\mathrm{ITT}}$) and compare them. The null value for a risk ratio, indicating no effect, is $1.0$. A value less than $1.0$ indicates a protective effect.\n\n**1. Per-Protocol (PP) Risk Ratio**\n\nThe per-protocol analysis, as defined, compares the risk in participants who fully adhered to the intervention protocol against the risk in those who fully adhered to the control protocol.\n\n- Risk in the per-protocol intervention group is $R_T = 0.10$.\n- Risk in the per-protocol control group is $R_C = 0.20$.\n\nThe per-protocol risk ratio is therefore:\n$$ \\mathrm{RR}_{\\mathrm{PP}} = \\frac{R_T}{R_C} = \\frac{0.10}{0.20} = 0.50 $$\n\nThis represents the \"ideal\" or \"biologic\" effect of the intervention if received perfectly.\n\n**2. Intention-to-Treat (ITT) Risk Ratio**\n\nThe intention-to-treat analysis compares the average risk in all participants as they were initially randomized, regardless of subsequent adherence.\n\n- **ITT Risk in the Intervention Arm ($R_{\\mathrm{ITT, int}}$):**\nThis is the weighted average risk of the participants randomized to the intervention arm. A proportion $p_{int,adh} = 0.60$ adhered (risk $R_{int,adh} = 0.10$), and a proportion $p_{int,disc} = 0.40$ discontinued (risk $R_{int,disc} = 0.16$).\n$$ R_{\\mathrm{ITT, int}} = (p_{int,adh} \\times R_{int,adh}) + (p_{int,disc} \\times R_{int,disc}) $$\n$$ R_{\\mathrm{ITT, int}} = (0.60 \\times 0.10) + (0.40 \\times 0.16) = 0.060 + 0.064 = 0.124 $$\n\n- **ITT Risk in the Control Arm ($R_{\\mathrm{ITT, ctl}}$):**\nThis is the weighted average risk of the participants randomized to the control arm. A proportion $p_{ctl,adh} = 0.65$ adhered (risk $R_{ctl,adh} = 0.20$), and a proportion $p_{ctl,swi} = 0.35$ switched to the intervention (risk $R_{ctl,swi} = 0.14$).\n$$ R_{\\mathrm{ITT, ctl}} = (p_{ctl,adh} \\times R_{ctl,adh}) + (p_{ctl,swi} \\times R_{ctl,swi}) $$\n$$ R_{\\mathrm{ITT, ctl}} = (0.65 \\times 0.20) + (0.35 \\times 0.14) = 0.130 + 0.049 = 0.179 $$\n\n- **ITT Risk Ratio ($\\mathrm{RR}_{\\mathrm{ITT}}$):**\nThe ITT risk ratio is the ratio of these two average risks.\n$$ \\mathrm{RR}_{\\mathrm{ITT}} = \\frac{R_{\\mathrm{ITT, int}}}{R_{\\mathrm{ITT, ctl}}} = \\frac{0.124}{0.179} \\approx 0.6927... $$\nRounding to two decimal places, $\\mathrm{RR}_{\\mathrm{ITT}} \\approx 0.69$.\n\n**3. Comparison and Interpretation**\n\nWe have $\\mathrm{RR}_{\\mathrm{PP}} = 0.50$ and $\\mathrm{RR}_{\\mathrm{ITT}} \\approx 0.69$.\nThe null value is $1.0$. The per-protocol effect estimate ($0.50$) is farther from the null than the intention-to-treat effect estimate ($0.69$). This means the ITT effect is \"attenuated\" or \"biased toward the null\" relative to the PP effect.\n\nThis attenuation occurs for two reasons, both stemming from non-adherence:\n- In the intervention arm, a substantial fraction ($0.40$) stopped the beneficial intervention and were exposed to the higher-risk control condition. This \"dilutes\" the protective effect in the intervention arm, increasing its average risk from $0.10$ to $0.124$.\n- In the control arm, a substantial fraction ($0.35$) switched to the beneficial intervention. This \"contaminates\" the control arm, decreasing its average risk from $0.20$ to $0.179$.\n\nBoth phenomena—increasing the risk in the numerator and decreasing the risk in the denominator—push the risk ratio $\\mathrm{RR}_{\\mathrm{ITT}}$ closer to $1.0$ compared to $\\mathrm{RR}_{\\mathrm{PP}}$.\n\n### Evaluation of Options\n\n**A. The intention-to-treat risk ratio equals the per-protocol risk ratio at $0.50$ because randomization balances nonadherence, so deviations do not affect the contrast.**\n- Our calculation shows $\\mathrm{RR}_{\\mathrm{ITT}} \\approx 0.69$ and $\\mathrm{RR}_{\\mathrm{PP}} = 0.50$. They are not equal. The reasoning is also false; randomization balances baseline characteristics but does not prevent or necessarily balance post-randomization non-adherence. Deviations clearly affect the contrast.\n- **Verdict: Incorrect.**\n\n**B. The intention-to-treat risk ratio is attenuated toward the null relative to the per-protocol risk ratio, approximately $0.69$ versus $0.50$, due to discontinuation in the intervention arm increasing its average risk and switching in the control arm decreasing its average risk.**\n- This matches our calculations ($\\mathrm{RR}_{\\mathrm{ITT}} \\approx 0.69$, $\\mathrm{RR}_{\\mathrm{PP}} = 0.50$). It correctly identifies that the ITT risk ratio is attenuated (closer to the null value of $1.0$). The provided reasoning—that discontinuers increase the intervention arm's average risk and switchers decrease the control arm's average risk—is precisely the mechanism for this attenuation, as derived above.\n- **Verdict: Correct.**\n\n**C. The intention-to-treat risk ratio is stronger (farther from $1$) than the per-protocol risk ratio, approximately $0.40$, because excluding nonadherers reduces bias and increases the contrast.**\n- The calculated $\\mathrm{RR}_{\\mathrm{ITT}}$ is approximately $0.69$, not $0.40$. The claim that the ITT ratio is \"stronger\" is the opposite of what occurred; it is weaker (attenuated). Furthermore, the ITT analysis *includes* nonadherers by definition; it does not exclude them.\n- **Verdict: Incorrect.**\n\n**D. The intention-to-treat risk ratio reverses direction (greater than $1$), approximately $1.10$, due to differential nonadherence overwhelming randomization.**\n- Our calculation shows $\\mathrm{RR}_{\\mathrm{ITT}} \\approx 0.69$, which is less than $1.0$. The protective effect, while attenuated, has not reversed direction. The calculated value is not approximately $1.10$.\n- **Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The final practice challenges you to think like a trial analyst by identifying common pitfalls that violate the ITT principle. Real-world trials face issues like missing data and participants dying before the study ends, which can complicate the analysis. This problem requires you to distinguish between analytical strategies that break randomization and those that correctly handle these issues to preserve the ITT estimand, reinforcing the rule to \"analyze all participants as randomized.\" ",
            "id": "4603249",
            "problem": "A randomized controlled trial enrolls $N$ adults and assigns them in equal proportions to a novel antihypertensive strategy ($Z=1$) versus usual care ($Z=0$). The primary endpoint is systolic blood pressure at $t=12$ months, denoted $Y$. After randomization, some participants do not adhere to their assigned strategy or cross over; let $A$ be an adherence indicator measured after randomization ($A=1$ for adherent, $A=0$ for nonadherent). A post-randomization biomarker $M$ is measured at $t=3$ months. Some participants die before $t=12$ months (indicator $D=1$), and some are lost to follow-up (outcome missingness indicator $R=1$ if $Y$ observed, $R=0$ otherwise). Investigators target the intention-to-treat estimand, the average causal effect of assignment on the endpoint, expressed as\n$$\n\\Delta_{\\mathrm{ITT}} \\equiv \\mathbb{E}\\big[Y \\mid Z=1\\big] - \\mathbb{E}\\big[Y \\mid Z=0\\big],\n$$\nwith the understanding that the endpoint must be defined for all randomized participants. Assume $Z$ is randomized and hence independent of all pre-randomization covariates $L_0$, and that the study collected rich baseline data $L_0$ on all $N$ participants.\n\nSeveral analysis teams propose a pitfall (an analytical choice that violates intention-to-treat thinking) along with a corresponding correction they claim preserves the intention-to-treat estimand. Which of the following options correctly pair a pitfall that violates intention-to-treat analysis with a corrected strategy that preserves the estimand $\\Delta_{\\mathrm{ITT}}$? Select all that apply.\n\nA. Pitfall: Exclude participants who did not adhere ($A=0$) or who crossed over, and compare mean $Y$ between the remaining groups. Correction: Use inverse probability weights based on $A$ to estimate the effect among adherers (a per-protocol effect).\n\nB. Pitfall: Perform a complete-case analysis that drops participants with $R=0$. Correction: Impute missing $Y$ under a model that conditions on $Z$ and baseline covariates $L_0$ (but not on any post-randomization variables), create multiple completed datasets, and estimate $\\Delta_{\\mathrm{ITT}}$ by comparing groups defined by $Z$ in each imputed dataset with combination by Rubin’s rules.\n\nC. Pitfall: Adjust for the post-randomization biomarker $M$ in a regression of $Y$ on $Z$ and $M$ to “improve precision.” Correction: Include $M$ as a covariate so that residual variation unrelated to $M$ is compared between $Z=1$ and $Z=0$.\n\nD. Pitfall: Exclude participants who die before $t=12$ months ($D=1$) to avoid “undefined” $Y$. Correction: Redefine the endpoint so that death before $t=12$ months is assigned the worst possible outcome value and include all randomized participants in the analysis by $Z$.\n\nE. Pitfall: Conduct an “as-treated” analysis that compares those who actually received the novel strategy to those who did not, regardless of $Z$. Correction: Apply two-stage least squares with $Z$ as an instrument for treatment received to remove confounding by $A$.\n\nYour answer should identify all and only the options in which the pitfall indeed violates intention-to-treat analysis and the proposed correction preserves the intention-to-treat estimand as defined above.",
            "solution": "The problem statement is first validated to ensure it is scientifically sound, well-posed, and objective.\n\n### Step 1: Extract Givens\n-   A randomized controlled trial (RCT) enrolls $N$ adults.\n-   Randomization is to a novel antihypertensive strategy ($Z=1$) versus usual care ($Z=0$), in equal proportions.\n-   $Z$ is independent of all pre-randomization covariates $L_0$, i.e., $Z \\perp L_0$.\n-   The primary endpoint is systolic blood pressure at $t=12$ months, denoted $Y$.\n-   $A$ is a post-randomization adherence indicator ($A=1$ for adherent, $A=0$ for nonadherent).\n-   $M$ is a post-randomization biomarker measured at $t=3$ months.\n-   $D$ is an indicator for death before $t=12$ months ($D=1$ if died).\n-   $R$ is an indicator for missingness of the outcome $Y$ ($R=1$ if $Y$ is observed, $R=0$ otherwise).\n-   Rich baseline data $L_0$ are available for all $N$ participants.\n-   The target estimand is the intention-to-treat (ITT) effect: $\\Delta_{\\mathrm{ITT}} \\equiv \\mathbb{E}\\big[Y \\mid Z=1\\big] - \\mathbb{E}\\big[Y \\mid Z=0\\big]$.\n-   A key premise is that the endpoint $Y$ must be defined for all randomized participants.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded (Critical)**: The problem describes a standard scenario in a clinical trial, incorporating common real-world complications such as non-adherence, missing data due to loss to follow-up, and death as a competing risk. The concepts presented—RCT, randomization, ITT analysis, per-protocol analysis, missing data, and competing risks—are fundamental to biostatistics and epidemiology. The problem is scientifically sound.\n-   **Well-Posed**: The problem is well-posed. It clearly defines the setting, the variables, and the target estimand ($\\Delta_{\\mathrm{ITT}}$). The task is to evaluate several proposed analytical strategies against the established principles of ITT analysis. A unique and meaningful evaluation is possible for each option.\n-   **Objective (Critical)**: The problem is stated in precise, technical language common to the field of clinical trials. It is free from ambiguity, subjectivity, or opinion.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. I will proceed with the derivation of the solution and evaluation of the options.\n\nThe core principle of an intention-to-treat (ITT) analysis is to analyze all participants in the group to which they were randomly assigned, regardless of adherence, crossover, or other events occurring after randomization. This preserves the prognostic balance of measured and unmeasured covariates between the treatment and control groups that is achieved by randomization. The ITT estimand, $\\Delta_{\\mathrm{ITT}}$, measures the causal effect of *assignment* to a treatment strategy on the outcome in the entire population randomized. Any analysis that breaks randomization by excluding participants or adjusting for post-randomization variables on the causal pathway will generally be biased for this estimand.\n\nEach option will be evaluated based on whether its \"pitfall\" is a true violation of ITT principles and whether its \"correction\" is a valid method for preserving the ITT estimand, $\\Delta_{\\mathrm{ITT}}$.\n\n**Option A Evaluation**\n-   **Pitfall**: \"Exclude participants who did not adhere ($A=0$) or who crossed over, and compare mean $Y$ between the remaining groups.\" This is a classic violation of the ITT principle. Excluding participants based on a post-randomization behavior ($A$) breaks the randomization. The remaining groups are no longer guaranteed to be comparable because adherence can be related to prognosis. This type of analysis, often called a \"per-protocol\" or \"on-treatment\" analysis, is susceptible to selection bias. The pitfall is correctly identified as a violation of ITT analysis.\n-   **Correction**: \"Use inverse probability weights based on $A$ to estimate the effect among adherers (a per-protocol effect).\" This correction describes a valid method, under certain assumptions, for estimating a causal effect. However, as explicitly stated, it targets the \"per-protocol effect,\" which is the effect of treatment receipt among the subpopulation of adherers. This is a fundamentally different estimand from the ITT effect, $\\Delta_{\\mathrm{ITT}}$, which is the effect of treatment assignment among the entire randomized population. Therefore, this correction does not preserve the ITT estimand.\n-   **Verdict**: Incorrect. The proposed correction targets a different estimand.\n\n**Option B Evaluation**\n-   **Pitfall**: \"Perform a complete-case analysis that drops participants with $R=0$.\" This violates the ITT principle of including all randomized participants. If the reason for missingness is related to both treatment and outcome (i.e., data are not Missing Completely At Random or MCAR), this will induce selection bias. Even under the less restrictive Missing At Random (MAR) assumption, a complete-case analysis can be biased. The pitfall is correctly identified.\n-   **Correction**: \"Impute missing $Y$ under a model that conditions on $Z$ and baseline covariates $L_0$ (but not on any post-randomization variables), create multiple completed datasets, and estimate $\\Delta_{\\mathrm{ITT}}$ by comparing groups defined by $Z$ in each imputed dataset with combination by Rubin’s rules.\" This describes a standard, principled approach for handling missing data in an ITT analysis under the MAR assumption (i.e., missingness depends only on observed data like $Z$ and $L_0$). By imputing the missing outcomes, it allows the analysis to include all randomized participants. Critically, the imputation model avoids using post-randomization information that could introduce bias, and the subsequent analysis respects the original randomization by comparing groups based on $Z$. This procedure is designed to provide an unbiased estimate of $\\Delta_{\\mathrm{ITT}}$ for the full cohort.\n-   **Verdict**: Correct. The pitfall is an ITT violation, and the correction is a valid method to handle missing data while preserving the ITT estimand.\n\n**Option C Evaluation**\n-   **Pitfall**: \"Adjust for the post-randomization biomarker $M$ in a regression of $Y$ on $Z$ and $M$ to “improve precision.”\" This is a violation of sound analytical practice for estimating the total ITT effect. The biomarker $M$ is measured after randomization and may be on the causal pathway from treatment assignment $Z$ to outcome $Y$ (i.e., $Z \\rightarrow M \\rightarrow Y$). Adjusting for such a variable blocks a portion of the treatment effect, leading to a biased estimate of the total effect $\\Delta_{\\mathrm{ITT}}$. It could also induce collider-stratification bias if $M$ is a common effect of $Z$ and an unmeasured cause of $Y$. The pitfall is correctly identified.\n-   **Correction**: \"Include $M$ as a covariate so that residual variation unrelated to $M$ is compared between $Z=1$ and $Z=0$.\" This is not a \"correction\" but a restatement and flawed justification of the pitfall. It describes the goal of the incorrect adjustment but does not remedy its fundamental flaw. The estimand targeted by this adjusted analysis is the direct effect of $Z$ on $Y$ not mediated by $M$, which is not the total ITT effect $\\Delta_{\\mathrm{ITT}}$.\n-   **Verdict**: Incorrect. The proposed correction is not a correction and does not preserve the ITT estimand.\n\n**Option D Evaluation**\n-   **Pitfall**: \"Exclude participants who die before $t=12$ months ($D=1$) to avoid “undefined” $Y$.\" This is a severe violation of the ITT principle. Death is an outcome that is often affected by the intervention. Excluding participants who died is a form of conditioning on survival, a post-randomization event, which can lead to significant selection bias. For example, if a treatment prevents death, the treated group at $t=12$ months will contain more frail individuals who would have died in the control arm, potentially making the treatment appear worse on the outcome $Y$ among survivors. The pitfall is correctly identified.\n-   **Correction**: \"Redefine the endpoint so that death before $t=12$ months is assigned the worst possible outcome value and include all randomized participants in the analysis by $Z$.\" This is a valid and common strategy for handling the competing risk of death in an ITT analysis. The problem statement itself requires that $Y$ be defined for all participants. This correction fulfills that requirement by creating a composite outcome (e.g., a ranked outcome where death is the worst rank, or assigning a specific unfavorable value for $Y$ like a very high blood pressure). This allows all randomized individuals to be included in their assigned groups, thereby fully adhering to the ITT principle. This method estimates the treatment effect on a meaningful, composite endpoint for the entire randomized cohort.\n-   **Verdict**: Correct. The pitfall is an ITT violation, and the correction is a valid method to handle a competing risk while preserving the ITT principle.\n\n**Option E Evaluation**\n-   **Pitfall**: \"Conduct an “as-treated” analysis that compares those who actually received the novel strategy to those who did not, regardless of $Z$.\" This completely discards randomization, the cornerstone of the trial. The comparison is now observational and highly susceptible to confounding by indication (i.e., the reasons a person actually received the treatment are related to their prognosis). This is a flagrant violation of ITT. The pitfall is correctly identified.\n-   **Correction**: \"Apply two-stage least squares with $Z$ as an instrument for treatment received to remove confounding by $A$.\" This describes an Instrumental Variable (IV) analysis. While IV is a valid method for estimating a causal effect in the presence of non-compliance, it does not estimate the ITT effect. Under its standard assumptions, IV analysis estimates the Complier Average Causal Effect (CACE), which is the effect of actually receiving the treatment among the specific subpopulation of individuals who comply with their treatment assignment. The CACE is a different estimand from $\\Delta_{\\mathrm{ITT}}$.\n-   **Verdict**: Incorrect. The proposed correction targets a different estimand (CACE), not the ITT estimand.\n\nIn summary, options B and D correctly identify a pitfall that violates ITT analysis and a corresponding correction that validly aims to preserve the ITT estimand by including all randomized participants in the analysis.",
            "answer": "$$\\boxed{BD}$$"
        }
    ]
}